NNZ-2591 Angelman top-line results presentation
Released
Released
Announcement PDF
NNZ-2591 Angelman
syndrome Phase 2 trial
top-line results
9 August 2024
IMPROVING THE LIVES OF PEOPLE WITH
NEURODEVELOPMENTAL DISABILITIES
Page□1
Forward looking statements
This presentation contains forward looking statements that involve
risks and uncertainties. Although we believe that the expectations
reflected in the forward looking statements are reasonable at this
time, Neuren can give no assurance that these expectations will
prove to be correct. Actual results could differ materially from those
anticipated. Reasons may include risks associated with drug
development and manufacture, risks inherent in the regulatory
processes, delays in clinical trials, risks associated with patent
protection, future capital needs or other general risks or factors.
2
Angelman syndrome (AS) overview
Cause of the syndrome
Deletion or variation in the
maternal allele of the UBE3A
gene on chromosome 15
Broad and severe impact on life
Intellectual impairment
Behavioural issues
Sleep disorders
Seizures
Language deficits
Sucking or feeding difficulties
UBE3A protein plays a role
in the formation,
maintenance and function
of dendrites and synapses
Motor delays
Hand-flapping
Ataxia
Curvature of the spinal cord
Hypopigmentation
GI dysfunction (constipation)
Movement and balance disorder
1 https://unitedbrainassociation.org/2021/03/23/rowan-smiths-brain-story
Patients stories
“It has impacted our lives in almost every aspect.
Day-to-day challenges are always present. Rowan
brings us incredible joy, and we are so happy to be
his parents. We are no longer saving for college
but saving for Rowan’s long-term care, legal
navigating, and learning about special needs
trusts. We need to find ways to protect and care
for Rowan for the rest of his life, even after we are
gone…Rowan not being able to tell us how his day
was, or if he doesn’t feel right. Wanting to make
sure he has friends and is included in social
settings. We don’t want him to be left behind
because of his diagnosis.”1
“When I got the call about his diagnosis while I was
at work, I immediately started looking up
information online to learn about Angelman
syndrome, as we had never heard of it before. I
looked at the possibilities and what to expect, and I
was devastated and torn-up inside… we can and
will do whatever we can to make sure Drew
reaches his maximum potential, whatever that
might be.” 2
2 https://globalgenes.org/story/journey-towards-a-diagnosis-diagnosing-a-rare-form-of-angelman-syndrome/
3
Consistent efficacy observed for NNZ-2591 in Ube3am-/p+ mouse model of AS
Hypoactivity & anxiety
Sociability
Daily living
Motor
Daily living
Cognition
4
Phase 2 clinical trial results highlights
•
NNZ-2591 was safe and well tolerated, with no serious adverse events and no meaningful trends in
laboratory values or other safety parameters during treatment
•
Clinician and caregiver global efficacy measures specifically designed for AS showed a level of
improvement from baseline that was statistically significant1 and considered clinically meaningful:
•
AS Clinical Global Impression of Improvement (CGI-I) - mean score of 3.0, with 11 out of 13 children
showing improvement assessed by clinicians (p=0.0010)
•
AS Caregiver Overall Impression of Change (CIC) – mean score of 3.2, with 8 out of 12 children showing
improvement assessed by caregivers (p=0.0273)
•
Every child in the younger age segment of 3-12 years showed improvement measured by both the
CGI-I (mean score 2.8 p=0.0078) and the CIC (mean score 2.6 p=0.0078)
•
Improvements were seen in clinically important aspects of Angelman syndrome, including
communication, behavior, cognition and motor abilities
•
Results further strengthen confidence in potential of NNZ-2591 for multiple neurodevelopmental
disorders, independent of origin of underlying genetics
1 Wilcoxon signed rank test p<0.05
5
Phase 2 Clinical
Trial Design
6
Neuren’s Phase 2 trial in children with Angelman syndrome
First study in pediatric patients, to inform future development
3 AU sites: Austin Health,
Sydney Children’s Hospital,
Children’s Health Queensland
Hospital
NNZ-2591 treatment
Screening
/Baseline
Follow-up
Up-titration to
12 mg/kg BID
16 subjects, age 4-17
Week 0
Primary endpoints
Week 4
Week 10
Week 17
Week 19
Secondary endpoints
A range of efficacy measurements, including measures specifically designed for AS
and measures used in other developmental conditions
Safety, tolerability and PK
Key global measures specifically designed for AS: CGI-I, CIC and CGI-S
Bayley Scales of Infant and Toddler Development (Bayley-4) included as exploratory
efficacy measures, although designed to measure outcomes over a longer time
period than the duration of this trial.
7
Participant Disposition
17 participants
16 enrolled
(ITT1 Population)
1 screen failure
Discontinuations:
1 due to inability to comply with study related safety measures;
1 due to protocol deviation (COVID-19 during screening);
1 due to Treatment Emergent Adverse Event (TEAE) (COVID-19)
13 completers
(mITT2 Population)
1 Intention-to-Treat
2 Modified Intention-to-Treat
8
Enrolled demographics
Low Developmental Quotient (DQ) score reflecting severity of the syndrome
Sex
Age
Mean
10.1yrs
Median
9.5yrs
3-12yrs: N = 10
13-17yrs: N = 6
Genotype
Cognitive level
(non-verbal DQ)
Non
Deletion,
7, 44%
Female,
9, 56%
CGI-S
(at Baseline)
>=20,
n=4,
25%
Mean (SD):
4.8 (0.75)
Male,
7, 44%
Deletion,
9, 56%
<20,
n=12,
75%
Completers average DQ: 12
9
Safety and
Tolerability
10
Safety and tolerability summary
NNZ-2591 was safe and well tolerated
✓ Well tolerated
TEAEs in 2 or more subjects
✓ Most TEAEs were mild to
moderate, and not drug
related
Event
N=16
n (%)
Event
N=16
n (%)
•
0 Serious TEAE
Viral Infection
5 (31)
Drooling
2 (13)
•
1 discontinuation due to
TEAE (COVID-19)
Nasopharyngitis
4 (25)
Epistaxis
2 (13)
Seizure
4 (25)
Insomnia
2 (13)
Upper Respiratory
Tract Infection
3 (19)
Pyrexia
2 (13)
Somnolence
3 (19)
Skin Abrasion
2 (13)
Constipation
3 (19)
Urinary Tract
Infection
2 (13)
Diarrhea
2 (13)
Vomiting
2 (13)
✓ No meaningful trends in
laboratory values,
electrocardiogram (ECG) or
other safety parameters
were observed during
treatment
11
Efficacy
12
Best practice implemented for AS-specific CGI-I and CIC measures
•
Both CGI-I and CIC scores
reflect overall improvement
from baseline
1 – Very Much Improved
Clinical Global Impression of
Improvement (CGI-I)
Caregiver Impression of
Change (CIC)
Scoring
Clinician gives an overall score
and scores each domain
Caregiver gives an overall
score and scores each domain
Also identifies the one symptom
area that has most influenced
his or her rating of the child’s
overall function
Domain
Anchors
•
Sleep
•
Behavior
•
Behavior
•
Communication
•
Communication
•
Motor abilities
•
Gross Motor Function
•
Seizures
•
Fine Motor/Oral Motor
Function
•
Cognitive abilities/ability to
learn
•
Self-care skills
•
GI Problems
2 – Much Improved
3 – “Minimally” Improved
4 – No Change
5 – “Minimally” Worse
6 – Much Worse
7 – Very Much Worse
•
•
All clinician raters completed
training to calibrate scoring and
interpretation of the scoring
anchors amongst raters
Training was done at study
start up and a follow-up
calibration training was done
during the study
13
AS CGI-I (clinician) results by subject and by domain
Mean CGI-I score of 3.0 (p=0.0010) with 11 out of 13 children showing improvement
CGI-I Overall Score by subject
Forest Plot of mean CGI-I Domain Scores
mITT Population
mITT Population
Subject
Improvement
14
AS CIC (caregiver) results by subject and by domain
Mean CIC score of 3.2 (p=0.0273) with 8 out of 121 children showing improvement
CIC Overall Score by subject
Forest Plot of mean CIC Domain Scores
mITT Population
mITT Population
Subject
Improvement
1 Score for one subject inadvertently not completed by caregiver at site visit
15
All children in 3 to 12 years age group improved
Mean CGI-I of 2.8 (p=0.0078) and mean CIC of 2.6 (p=0.0078) with all children showing
improvements
CGI-I Overall Score by subject
CIC Overall Score by subject
3-12 year old age group
3-12 year old age group
mITT Population
mITT Population
Subject
Subject
16
AS Clinical Global Impression of Severity (CGI-S)
4 subjects improved by one point on the overall CGI-S score after 13 weeks of treatment
Forest Plot of Change from Baseline in CGI-S Domain Scores
mITT Population
Improvement
17
Bayley-4 scales (raw scores)
Improvements observed despite treatment period of only 13 weeks
Cognitive Score by subject
Fine Motor Score by subject
Gross Motor Score by subject
mITT Population
mITT Population
mITT Population
Improvement
Improvement
54% shown improvement
Subject
62% shown improvement
Subject
Improvement
54% shown improvement
Subject
Expressive Communication Score by subject
Receptive Communication Score by subject
Social-Emotional Score by subject
mITT Population
mITT Population
mITT Population
Improvement
62% shown improvement
Subject
Improvement
62% shown improvement
Subject
Improvement
73% shown improvement
Subject
18
Clinician and caregiver testimonials
Clinicians
Caregivers
“Sleeps longer hours greater than 8 per night. Night
awakenings only to be covered but back to sleep on their
own. Wakes up much less.”
“…is more settled and focus on what they are doing …also
much more calmer than before.”
“Much Calmer. Focuses better. Hand flapping stopped.”
“More focused, balance, concentrate longer.”
“Understands more. Everything they are asked to do.”
“Shows more gestures by pointing and showing.”
“Steadier on feet. More balanced. Less cautious. Stair/curb
climbing managed on their own this week.”
“Can pick up small objects and try to do a puzzle”
“Family feel understanding more and more aware and feel
this is coming out as being more upset at times (ie
expressing feelings/needs).”
“Can sit at a table with the family without too much
behaviors spitting and hitting.”
“Following verbal instructions well without visual cues
(asking to get up or go to Grandmother).”
“Improved sleep, balance, no hand flapping, calmer.”
19
AS opportunity
20
AS has a well established global clinical environment
Estimated prevalence is 1/10,000 to 1/20,000 males and females1
Potential AS patients
US
Europe
Japan
China
Other2
12,000 – 25,0003
16,000 – 32,0003
3,000 - 7,0003
38,000 – 76,0003
12,000 - 25,0003
Natural history study since 2006 enrolled 550+ patients
to date
NIH funded
2006 – 2014
FDA funded
2018 – 2022
~300 patients
across 6 sites
in the US
~150 patients
across 10
sites in North
America
Global Angelman Syndrome Registry established in
Sep 2016
ABOM
funded
2022 –
present
Currently 2,510 registered patients across 95 countries
(966 in US and Canada)4
1 Angelman Syndrome Foundation (ASF) (www.angelman.org), Facts About Angelman Syndrome
2 Brazil, Israel, South Korea, Australia and New Zealand
3 Estimates based on United Nations population data 2022, derived by applying the estimated prevalence range to the populations under 60 years (urban population only for China)
4 https://www.angelmanregistry.info/ as at August 2024
21
Neuren has one of the leading programs for AS
Neuren Program Status
•
•
•
Orphan Drug
designation in US and
EU
Phase 2 clinical
development under
US FDA IND
Eligible for Rare
Pediatric Disease
Designation Priority
Review Voucher
program
Leading products in development
Company
#1
#2
#4
Delivery
Mechanism
Product
Development Stage
RNA
Spinal
injections
Phase 3 to
commence by end
of 2024
RNA
Spinal
injections
Phase 3 to
commence H1
2025
Small
Molecule
Oral
Successful
Phase 2
Small
Molecule
Oral
Phase 2a (top line
results 2025E1)
Modalities
Neuren engaging with all
stakeholders
Leading clinicians
1 Broker estimates
22
NNZ-2591 as a
multi-indication
platform
23
Phase 2 trial results validating multi-indication platform
General safety & tolerability
Serious TEAEs
Mean CGI-I
(% shown improvement)
Mean CIC
(% shown improvement)
# patients had CGI-S
improvement of 1
(% of patients)
Consistent improvement in
clinically important aspects
Phelan-McDermid syndrome
N=18, 13 weeks
Pitt Hopkins syndrome
N=11, 13 weeks
Angelman syndrome
N=13, 13 weeks
Safe and well tolerated, with no
meaningful trends in laboratory
values or other safety
parameters during treatment
Safe and well tolerated, with no
meaningful trends in laboratory
values or other safety
parameters during treatment
Safe and well tolerated, with no
meaningful trends in laboratory
values or other safety
parameters during treatment
1 unrelated to drug
0
0
2.4
(89%)
2.6
(82%)
All
3-12 yr old
3.0
(85%)
2.8
(100%)
All
3-12 yr old
3.2
(67%)
2.6
(100%)
2.7
(83%)
3.0
(73%)
7
(39%)
6
(55%)
4
(31%)
Communication, behavior,
cognition, social
Communication, social,
cognition, motor
Communication, behavior,
cognition, motor
24
Multiple indications opportunity for NNZ-2591
•
Positive results from Phelan
McDermid syndrome, Pitt Hopkins
syndrome and Angelman syndrome
Phase 2 trials
•
End of Phase 2 meeting with FDA
for Phelan McDermid syndrome
scheduled for September 2024
•
US IND open for Prader-Willi syndrome
•
Advancing non-clinical studies in
multiple undisclosed indications
•
Rett and Fragile X syndromes are
licensed to Acadia, with same
economics to Neuren as trofinetide;
Neuren retains worldwide rights to all
other indications
Prader-Willi
syndrome
Pitt Hopkins
syndrome
NNZ-2591
PhelanMcDermid
syndrome
Angelman
syndrome
Other
undisclosed
indications
Rett
syndrome
(Acadia)
Fragile X
syndrome
(Acadia)
25
CONTACT
investorrelations@neurenpharma.com
26
Share your feedback
Discover